Have a feature idea you'd love to see implemented?
Let us know!
PRTA Prothena Corp Public Ltd Co
Price (delayed)
$18.18
Market cap
$977.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$425.72M
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating
Highlights
The company's gross profit has surged by 143% QoQ
Prothena's revenue has soared by 143% from the previous quarter
The quick ratio has increased by 31% year-on-year but it has declined by 4.7% since the previous quarter
Key stats
What are the main financial stats of PRTA
Market
Valuations
Earnings
Shares outstanding
53.78M
Market cap
$977.73M
Enterprise value
$425.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
4.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.96
Revenue
$217.25M
EBIT
-$61.4M
EBITDA
-$54.76M
Free cash flow
-$100.81M
Per share
Balance sheet
Liquidity
EPS
-$0.95
Free cash flow per share
-$1.87
Book value per share
$10.82
Revenue per share
$4.04
TBVPS
$12.01
Total assets
$645.57M
Total liabilities
$63.65M
Debt
$12.12M
Equity
$581.92M
Working capital
$539.23M
Debt to equity
0.02
Current ratio
12.54
Quick ratio
12.07
Net debt/EBITDA
10.08
Margins
Efficiency
Dividend
EBITDA margin
-25.2%
Gross margin
100%
Net margin
-23.4%
Operating margin
-42.1%
Return on assets
-7.5%
Return on equity
-9%
Return on invested capital
-158.9%
Return on capital employed
-10.3%
Return on sales
-28.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRTA stock price
How has the Prothena stock price performed over time
Intraday
-0.55%
1 week
9.58%
1 month
8.67%
1 year
-48.75%
YTD
-49.97%
QTD
8.67%
Financial performance
How have Prothena's revenue and profit performed over time
Revenue
$217.25M
Gross profit
$217.25M
Operating income
-$91.36M
Net income
-$50.92M
Gross margin
100%
Net margin
-23.4%
The company's gross profit has surged by 143% QoQ
Prothena's revenue has soared by 143% from the previous quarter
Prothena's net margin has soared by 90% YoY and by 88% from the previous quarter
The operating margin has soared by 86% year-on-year and by 83% since the previous quarter
Growth
What is Prothena's growth rate over time
Valuation
What is Prothena stock price valuation
P/E
N/A
P/B
1.68
P/S
4.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.96
The company's EPS has surged by 70% QoQ and by 65% YoY
PRTA's price to book (P/B) is 58% lower than its 5-year quarterly average of 4.0 and 45% lower than its last 4 quarters average of 3.1
The company's equity rose by 16% QoQ
Prothena's revenue has soared by 143% from the previous quarter
PRTA's price to sales (P/S) is 98% lower than its 5-year quarterly average of 261.3 and 70% lower than its last 4 quarters average of 14.9
Efficiency
How efficient is Prothena business performance
The ROIC has soared by 94% YoY and by 79% from the previous quarter
The company's return on sales has surged by 89% YoY and by 86% QoQ
The ROE has soared by 70% from the previous quarter and by 65% YoY
Prothena's return on assets has surged by 70% QoQ and by 63% YoY
Dividends
What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRTA.
Financial health
How did Prothena financials performed over time
The total liabilities has dropped by 54% year-on-year and by 47% since the previous quarter
PRTA's current ratio is up by 33% year-on-year but it is down by 4.1% since the previous quarter
Prothena's debt is 98% less than its equity
Prothena's debt to equity has surged by 100% YoY
The company's equity rose by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.